D Santos García1, E Suárez Castro2, I Expósito2, T de Deus2, C Tuñas2, A Aneiros2, M López Fernández2, D Núñez Arias3, M Bermúdez Torres4. 1. Section of Neurology, Complejo Hospitalario Universitario de Ferrol (CHUF), Hospital A. Marcide, Ferrol, A Coruña, Spain. Electronic address: diegosangar@yahoo.es. 2. Section of Neurology, Complejo Hospitalario Universitario de Ferrol (CHUF), Hospital A. Marcide, Ferrol, A Coruña, Spain. 3. Department of Psychiatry, Complejo Hospitalario Universitario de Ferrol (CHUF), Hospital Naval, Ferrol, A Coruña, Spain. 4. Department of Family Medicine, Complejo Hospitalario Universitario de Ferrol (CHUF), Ferrol, A Coruña, Spain.
Abstract
BACKGROUND AND OBJECTIVE: To study what comorbid conditions were present at baseline and 3years later in a cohort of Spanish Parkinson's disease (PD) patients, to compare comorbidity with both Alzheimer's disease (AD) and control groups and to analyze the role of comorbidity as predictor of mortality. METHODS: One hundred and forty-seven non-demented PD patients (57.1% males; 70.9±8.6years old) were included in this 36months follow-up (2012-2015), monocenter, evaluation study. The International Classification of Diseases, Tenth Revision (ICD-10), Charlson Index (CI), Comorbidity-Polypharmacy Score (CPS) and Elixhauser Comorbidity Measure (ECM) were used to assess comorbidity at baseline and at 3years. Forty-four AD patients and 44 control subjects were included as comparator groups. RESULTS: Total number of comorbidities (ICD-10) and polypharmacy at baseline were higher in PD and AD patients than controls (4.4±2.3 vs 5.2±2.4 vs 3.4±1.9 [p=0.001] and 81.6% vs 75% vs 56.8% [p=0.003], respectively). Diseases of the circulatory system (ICD-10/chapter-IX) and endocrine, nutritional and metabolic diseases (ICD-10/chapter-IV) were the most frequent in all groups. There was a significant increase in comorbidity (mean, +1.6±2.8) in all groups (p<0.0001) without differences between them. Seventeen patients died and 8 cases were did not follow-up. Comorbidity was a predictor of death in PD patients after adjust for other covariates (including age, sex, disease duration, disease stage, motor status and non-motor symptoms): ICD-10 (total number of comorbidities), hazard ratio 1.285 (95% confidence interval, 1.047-1.577; p=0.017); CI, hazard ratio 1.462 (95% confidence interval, 1.045-2.047; p=0.027). CONCLUSIONS: Comorbidity is frequent in PD patients, increases significantly over time and predicts mortality.
BACKGROUND AND OBJECTIVE: To study what comorbid conditions were present at baseline and 3years later in a cohort of Spanish Parkinson's disease (PD) patients, to compare comorbidity with both Alzheimer's disease (AD) and control groups and to analyze the role of comorbidity as predictor of mortality. METHODS: One hundred and forty-seven non-demented PDpatients (57.1% males; 70.9±8.6years old) were included in this 36months follow-up (2012-2015), monocenter, evaluation study. The International Classification of Diseases, Tenth Revision (ICD-10), Charlson Index (CI), Comorbidity-Polypharmacy Score (CPS) and Elixhauser Comorbidity Measure (ECM) were used to assess comorbidity at baseline and at 3years. Forty-four ADpatients and 44 control subjects were included as comparator groups. RESULTS: Total number of comorbidities (ICD-10) and polypharmacy at baseline were higher in PD and ADpatients than controls (4.4±2.3 vs 5.2±2.4 vs 3.4±1.9 [p=0.001] and 81.6% vs 75% vs 56.8% [p=0.003], respectively). Diseases of the circulatory system (ICD-10/chapter-IX) and endocrine, nutritional and metabolic diseases (ICD-10/chapter-IV) were the most frequent in all groups. There was a significant increase in comorbidity (mean, +1.6±2.8) in all groups (p<0.0001) without differences between them. Seventeen patientsdied and 8 cases were did not follow-up. Comorbidity was a predictor of death in PDpatients after adjust for other covariates (including age, sex, disease duration, disease stage, motor status and non-motor symptoms): ICD-10 (total number of comorbidities), hazard ratio 1.285 (95% confidence interval, 1.047-1.577; p=0.017); CI, hazard ratio 1.462 (95% confidence interval, 1.045-2.047; p=0.027). CONCLUSIONS: Comorbidity is frequent in PDpatients, increases significantly over time and predicts mortality.
Authors: Nicol G M Oonk; Kris L L Movig; Job van der Palen; Henk-Willem Nijmeijer; Mirjam E van Kesteren; Lucille D A Dorresteijn Journal: Clin Drug Investig Date: 2021-08-10 Impact factor: 2.859
Authors: Diego Santos-García; T de Deus Fonticoba; E Suárez Castro; A Aneiros Díaz; J M Paz González; M J Feal Panceiras; C García Sancho; S Jesús; P Mir; M Aguilar; P Pastor; J Hernández Vara; O de Fábregues-Boixar; V Puente; A Crespo Cuevas; I González-Aramburu; J Infante; F Carrillo Padilla; M Pueyo; S Escalante; N Bernardo; B Solano; A Cots Foraster; P Martinez-Martin Journal: J Neural Transm (Vienna) Date: 2019-10-31 Impact factor: 3.575
Authors: Jenni Ilomäki; J Simon Bell; Adrienne Y L Chan; Anna-Maija Tolppanen; Hao Luo; Li Wei; Edward Chia-Cheng Lai; Ju-Young Shin; Giorgia De Paoli; Romin Pajouheshnia; Frederick K Ho; Lorenna Reynolds; Kui Kai Lau; Stephen Crystal; Wallis C Y Lau; Kenneth K C Man; Ruth Brauer; Esther W Chan; Chin-Yao Shen; Ju Hwan Kim; Terry Y S Lum; Sirpa Hartikainen; Marjaana Koponen; Evelien Rooke; Marloes Bazelier; Olaf Klungel; Soko Setoguchi; Jill P Pell; Sharon Cook; Ian C K Wong Journal: CNS Drugs Date: 2020-09 Impact factor: 5.749
Authors: Daniel Zielonka; Grzegorz Witkowski; Elzbieta A Puch; Marta Lesniczak; Iwona Mazur-Michalek; Mark Isalan; Michal Mielcarek Journal: Front Med (Lausanne) Date: 2020-03-11